Promising Tools to Facilitate the Implementation of TDM of Biologics in Clinical Practice
Therapeutic drug monitoring (TDM) of biologics—encompassing the measurement of (trough) concentrations and anti-drug antibodies—is emerging as a valuable tool for clinical decision making. While this strategy needs further validation, attention on its implementation into the clinic is warranted. Rap...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-05-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/11/11/3011 |
| _version_ | 1797492980882341888 |
|---|---|
| author | Rani Soenen Christophe Stove Alessio Capobianco Hanne De Schutter Marie Dobbelaere Tahmina Mahjor Merel Follens Jo Lambert Lynda Grine |
| author_facet | Rani Soenen Christophe Stove Alessio Capobianco Hanne De Schutter Marie Dobbelaere Tahmina Mahjor Merel Follens Jo Lambert Lynda Grine |
| author_sort | Rani Soenen |
| collection | DOAJ |
| description | Therapeutic drug monitoring (TDM) of biologics—encompassing the measurement of (trough) concentrations and anti-drug antibodies—is emerging as a valuable tool for clinical decision making. While this strategy needs further validation, attention on its implementation into the clinic is warranted. Rapid testing and easy sampling are key to its implementation. Here, we aimed to evaluate the feasibility and volunteers’ perception of home microsampling for quantification of adalimumab (ADM) concentrations in psoriasis patients. In addition, we compared lateral flow testing (LFT) with enzyme-linked immunosorbent assay (ELISA). Patients participating in the SUPRA-A study (clinicaltrials.gov NCT04028713) were asked to participate in a substudy where volumetric absorptive microsampling (VAMS) was performed at home. At three time points, whole blood and corresponding serum samples were collected for ADM measurement using an in-house ELISA. In addition, the patients’ perspective on microsampling was evaluated via a questionnaire. LFT-obtained ADM concentrations agreed very well with ELISA results (Pearson’s correlation = 0.95 and R<sup>2</sup> = 0.89). ADM concentrations determined in both capillary (via finger prick) and corresponding venous blood VAMS samples correlated strongly with serum concentrations (Pearson’s correlation = 0.87). Our preliminary data (n = 7) on rapid testing and home-based microsampling are considered promising with regard to TDM implementation for adalimumab, warranting further research. |
| first_indexed | 2024-03-10T01:12:30Z |
| format | Article |
| id | doaj.art-b5da4c77764e4fe4a2472f1d23ae3786 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-10T01:12:30Z |
| publishDate | 2022-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-b5da4c77764e4fe4a2472f1d23ae37862023-11-23T14:15:15ZengMDPI AGJournal of Clinical Medicine2077-03832022-05-011111301110.3390/jcm11113011Promising Tools to Facilitate the Implementation of TDM of Biologics in Clinical PracticeRani Soenen0Christophe Stove1Alessio Capobianco2Hanne De Schutter3Marie Dobbelaere4Tahmina Mahjor5Merel Follens6Jo Lambert7Lynda Grine8Department of Dermatology, Ghent University Hospital, 9000 Ghent, BelgiumDepartment of Bioanalysis, Ghent University Hospital, 9000 Ghent, BelgiumDermatology Research Unit, University Ghent, 9000 Ghent, BelgiumDermatology Research Unit, University Ghent, 9000 Ghent, BelgiumDermatology Research Unit, University Ghent, 9000 Ghent, BelgiumDermatology Research Unit, University Ghent, 9000 Ghent, BelgiumDermatology Research Unit, University Ghent, 9000 Ghent, BelgiumDepartment of Dermatology, Ghent University Hospital, 9000 Ghent, BelgiumDepartment of Dermatology, Ghent University Hospital, 9000 Ghent, BelgiumTherapeutic drug monitoring (TDM) of biologics—encompassing the measurement of (trough) concentrations and anti-drug antibodies—is emerging as a valuable tool for clinical decision making. While this strategy needs further validation, attention on its implementation into the clinic is warranted. Rapid testing and easy sampling are key to its implementation. Here, we aimed to evaluate the feasibility and volunteers’ perception of home microsampling for quantification of adalimumab (ADM) concentrations in psoriasis patients. In addition, we compared lateral flow testing (LFT) with enzyme-linked immunosorbent assay (ELISA). Patients participating in the SUPRA-A study (clinicaltrials.gov NCT04028713) were asked to participate in a substudy where volumetric absorptive microsampling (VAMS) was performed at home. At three time points, whole blood and corresponding serum samples were collected for ADM measurement using an in-house ELISA. In addition, the patients’ perspective on microsampling was evaluated via a questionnaire. LFT-obtained ADM concentrations agreed very well with ELISA results (Pearson’s correlation = 0.95 and R<sup>2</sup> = 0.89). ADM concentrations determined in both capillary (via finger prick) and corresponding venous blood VAMS samples correlated strongly with serum concentrations (Pearson’s correlation = 0.87). Our preliminary data (n = 7) on rapid testing and home-based microsampling are considered promising with regard to TDM implementation for adalimumab, warranting further research.https://www.mdpi.com/2077-0383/11/11/3011psoriasisbiologicstherapeutic drug monitoringlateral flow testingmicrosampling |
| spellingShingle | Rani Soenen Christophe Stove Alessio Capobianco Hanne De Schutter Marie Dobbelaere Tahmina Mahjor Merel Follens Jo Lambert Lynda Grine Promising Tools to Facilitate the Implementation of TDM of Biologics in Clinical Practice Journal of Clinical Medicine psoriasis biologics therapeutic drug monitoring lateral flow testing microsampling |
| title | Promising Tools to Facilitate the Implementation of TDM of Biologics in Clinical Practice |
| title_full | Promising Tools to Facilitate the Implementation of TDM of Biologics in Clinical Practice |
| title_fullStr | Promising Tools to Facilitate the Implementation of TDM of Biologics in Clinical Practice |
| title_full_unstemmed | Promising Tools to Facilitate the Implementation of TDM of Biologics in Clinical Practice |
| title_short | Promising Tools to Facilitate the Implementation of TDM of Biologics in Clinical Practice |
| title_sort | promising tools to facilitate the implementation of tdm of biologics in clinical practice |
| topic | psoriasis biologics therapeutic drug monitoring lateral flow testing microsampling |
| url | https://www.mdpi.com/2077-0383/11/11/3011 |
| work_keys_str_mv | AT ranisoenen promisingtoolstofacilitatetheimplementationoftdmofbiologicsinclinicalpractice AT christophestove promisingtoolstofacilitatetheimplementationoftdmofbiologicsinclinicalpractice AT alessiocapobianco promisingtoolstofacilitatetheimplementationoftdmofbiologicsinclinicalpractice AT hannedeschutter promisingtoolstofacilitatetheimplementationoftdmofbiologicsinclinicalpractice AT mariedobbelaere promisingtoolstofacilitatetheimplementationoftdmofbiologicsinclinicalpractice AT tahminamahjor promisingtoolstofacilitatetheimplementationoftdmofbiologicsinclinicalpractice AT merelfollens promisingtoolstofacilitatetheimplementationoftdmofbiologicsinclinicalpractice AT jolambert promisingtoolstofacilitatetheimplementationoftdmofbiologicsinclinicalpractice AT lyndagrine promisingtoolstofacilitatetheimplementationoftdmofbiologicsinclinicalpractice |